Forfatter
Tittel Emerging strategies, applications and challenges of targeting NAD+ in the clinic
Medansvarlig Wang, He-Ling Lautrup, Sofie Nilsen, Hilde Loge Treebak, Jonas T. Watne, Leiv Otto Selbæk, Geir Wu, Lindsay E. Omland, Torbjørn Pirinen, Eija Cheung, Tin Cho Wang, Jun Ziegler, Mathias Tysnes, Ole-Bjørn Zapata-Pérez, Rubén Bruzzone, Santina Canto, Carles Deleidi, Michela Janssens, Georges E. Houtkooper, Riekelt H Scheibye-Knudsen, Morten Koshizaka, Masaya Yokote, Koutaro Verdin, Eric Bohr, Vilhelm A Tzourio, C Sinclair, D.R. Fang, Evandro Fei
Språk
Emne
Serie
Serienummer
År
Noter Abstract: Beyond their classical functions as redox cofactors, recent fundamental and clinical research has expanded our understanding of the diverse roles of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in signaling pathways, epigenetic regulation and energy homeostasis. Moreover, NAD and NADP influence numerous diseases as well as the processes of aging, and are emerging as targets for clinical intervention. Here, we summarize safety, bioavailability and efficacy data from NAD+-related clinical trials, focusing on aging and neurodegenerative diseases. We discuss the established NAD+ precursors nicotinic acid and nicotinamide, newer compounds such as nicotinamide riboside and nicotinamide mononucleotide, and emerging precursors. We also discuss technological advances including in industrial-scale production and real-time detection, which are facilitating NAD+ research and clinical translation. Finally, we emphasize the need for further large-scale studies to determine optimal dose, administration routes and frequency, as well as long-term safety and interindividual variability in response.
Tilgjengelige
L�nere p� venteliste
*000 ap
*00142478
*100 $aZhang, Jianying
*245 $aEmerging strategies, applications and challenges of targeting NAD+ in the clinic$cJianying Zhang, He-Ling Wang, Sofie Lautrup, Hilde Loge Nilsen, Jonas T Treebak, Leiv Otto Watne, Geir Selbæk, Lindsay E Wu, Torbjørn Omland, Eija Pirinen, Tin Cho Cheung, Jun Wang , Mathias Ziegler, Ole-Bjørn Tysnes, Rubén Zapata-Pérez, Santina Bruzzone, Carles Canto, Michela Deleidi, Georges E Janssens, Riekelt H Houtkooper, Morten Scheibye-Knudsen, Masaya Koshizaka, Koutaro Yokote, Eric Verdin, Vilhelm A Bohr, Charalampos Tzoulis, David A Sinclair, Evandro Fei Fang
*260 $c2025
*300 $ahttps://doi.org/10.1038/s43587-025-00947-6
*440 $aNature Aging$vsept 2025
*505 $aAbstract: Beyond their classical functions as redox cofactors, recent fundamental and clinical research has expanded our understanding of the diverse roles of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in signaling pathways, epigenetic regulation and energy homeostasis. Moreover, NAD and NADP influence numerous diseases as well as the processes of aging, and are emerging as targets for clinical intervention. Here, we summarize safety, bioavailability and efficacy data from NAD+-related clinical trials, focusing on aging and neurodegenerative diseases. We discuss the established NAD+ precursors nicotinic acid and nicotinamide, newer compounds such as nicotinamide riboside and nicotinamide mononucleotide, and emerging precursors. We also discuss technological advances including in industrial-scale production and real-time detection, which are facilitating NAD+ research and clinical translation. Finally, we emphasize the need for further large-scale studies to determine optimal dose, administration routes and frequency, as well as long-term safety and interindividual variability in response.
*650 $aAldring
*650 $aNevrodegenerative sykdommer
*700 $aWang, He-Ling
*700 $aLautrup, Sofie
*700 $aNilsen, Hilde Loge
*700 $aTreebak, Jonas T.
*700 $aWatne, Leiv Otto
*700 $aSelbæk, Geir
*700 $aWu, Lindsay E.
*700 $aOmland, Torbjørn
*700 $aPirinen, Eija
*700 $aCheung, Tin Cho
*700 $aWang, Jun
*700 $aZiegler, Mathias
*700 $aTysnes, Ole-Bjørn
*700 $aZapata-Pérez, Rubén
*700 $aBruzzone, Santina
*700 $aCanto, Carles
*700 $aDeleidi, Michela
*700 $aJanssens, Georges E.
*700 $aHoutkooper, Riekelt H
*700 $aScheibye-Knudsen, Morten
*700 $aKoshizaka, Masaya
*700 $aYokote, Koutaro
*700 $aVerdin, Eric
*700 $aBohr, Vilhelm A
*700 $aTzourio, C
*700 $aSinclair, D.R.
*700 $aFang, Evandro Fei
*856 $uhttps://doi.org/10.1038/s43587-025-00947-6
^
Det finnes ingen anmeldelser for denne boken.
Klikk her
for bli den første til å gi din mening